Use of antipsychotics and long-term risk of parkinsonism

Introduction Few epidemiological studies have assessed the risk of parkinsonisms after prolonged use of neuroleptics. We aimed to examine the long-term risk of degenerative parkinsonisms (DP) associated with previous use of neuroleptics. Methods All residents in Piedmont, Northern-west Italy, older than 39 years (2,526,319 subjects), were retrospectively followed up from 2013 to 2017. Exposure to neuroleptics was assessed through the regional archive of drug prescriptions. The development of DP was assessed using the regional archives of both drug prescriptions and hospital admissions. We excluded prevalent DP cases at baseline as well as those occurred in the first 18 months (short-term risk). The risk of DP associated with previous use of neuroleptics was examined through Cox regression, using a matched cohort design. Results The risk of DP was compared between 63,356 exposed and 316,779 unexposed subjects. A more than threefold higher risk of DP was observed among subjects exposed to antipsychotics, compared to those unexposed (HR = 3.27, 95% CI 3.00–3.57), and was higher for exposure to atypical than typical antipsychotics. The risk decreased after 2 years from therapy cessation but remained significantly elevated (HR = 2.38, 95% CI 1.76–3.21). Conclusions These results indicate a high risk of developing DP long time from the start of use and from the cessation for both typical and atypical neuroleptics, suggesting the need of monitoring treated patients even after long-term use and cessation.

Which medications can improve thinking, memory, behavior, or function?

Dementia disrupts a number of brain chemicals, and medications may be helpful to restore the balance of these neurotransmitters. When considering a new medication, it is important to set clear, measurable goals; start with a low dose; and track the effects over time. Cholinesterase inhibitors help with memory, mood, behavioral problems, and hallucinations; memantine helps with attention, alertness, mood, and behavioral problems; selective serotonin reuptake inhibitors (SSRIs) help with mood, anxiety, and behavioral problems; dextromethorphan/quinidine helps with inappropriate laughing or crying as well as behavioral problems; melatonin and acetaminophen help with sleep; atypical neuroleptics help with agitation, aggression, delusions, hallucinations, and picking; carbidopa/levodopa helps with walking, movement, and parkinsonian tremors; and beta blockers help with essential tremor. Clinical trials of new medications being developed may be available for those who are looking for better treatments for their loved one and for the next generation.

THE PROBLEM OF SYNTHETIC DRUG DEPENDENCE AND CURRENT APPROACHES TO PSYCHOPHARMACOTHERAPY

В работе представлен анализ современных литературных данных и данных клинической практики по применению атипичных нейролептиков в терапии психических и поведенческих расстройств. Показана эффективность применения нейролептика Оланзапин (Ферзапин) в лечении психических и поведенческих расстройств. The paper presents an analysis of contemporary literature and clinical practice data on the use of atypical neuroleptics in the treatment of psychiatric and behavioral disorders. The effectiveness of using the neuroleptic Olanzapine (Ferzapine) in the treatment of psychiatric and behavioral disorders is shown

Which medications can improve thinking, memory, behavior, or function?

Dementia disrupts a number of brain chemicals, and medications may be helpful to restore the balance of these neurotransmitters. When considering a new medication, it is important to set clear, measurable goals; start with a low dose; and track the effects over time. Cholinesterase inhibitors help with memory, mood, behavioral problems, and hallucinations; memantine helps with attention, alertness, mood, and behavioral problems; selective serotonin reuptake inhibitors (SSRIs) help with mood, anxiety, and behavioral problems; dextromethorphan/quinidine helps with inappropriate laughing or crying as well as behavioral problems; melatonin and acetaminophen help with sleep; atypical neuroleptics help with agitation, aggression, delusions, hallucinations, and picking; carbidopa/levodopa helps with walking, movement, and parkinsonian tremors; and beta blockers help with essential tremor. Clinical trials of new medications being developed may be available for those who are looking for better treatments for their loved one and for the next generation.

Clinical and Dynamic Characteristics оf Therapeutic Remissions after Acute Paranoid Psychoses in Schizophrenic Patients Treated with Antipsychotics of Various Generations

Background: the comparative aspect of the clinical-diagnostic and prognostic evaluation of long-term remissions treated with antipsychotics of various generations in patients with shift-like schizophrenia remains poorly studied and retains scientific and practical actuality. The purpose of the study: a comparative study of the therapeutic effect of antipsychotics of different generations on clinical-psychopathological peculiarities and the dynamics of 2-year remissions after acute paranoid states in patients with shift-like schizophrenia. Patients and methods: 34 female patients (average age made up 26.9 years old) were diagnosed in shift-like schizophrenia with a clinical picture of the attack as acute paranoid syndrome (F20.02 according to ICD-10). 16 patients received treatment with typical neuroleptics (TN), other 18 patients received atypical neuroleptics (ATN). The study was conducted as an open prospective, using clinical-psychopathological, clinical-catamnestic and clinical-psychometric methods. The mental state of patients was assessed four times: upon admission to the hospital in acute psychosis (1 point), when entering remission (2 points), after 1 and 2 years of remission (3 and 4 points). In psychometric assessment was used calculated for 1 patient indices of the main total score of all signs (MTS) and main score of 1 sign (MS) of the PANSS scale and its subscales of positive (P), negative (N) and general psychopathological (G) syndromes. Results: at the end of the active treatment with both types of antipsychotics at the 2 point of assessment, was reduced MS of positive symptoms P+G subscales from 3.3 to 1.7 scores on TN and from 3.8 to 2.2 scores on ATN, with a remission and stabilization of the achieved improvement with reduction of MS at 4 points up to 1.5. MS of negative symptoms by the 2 nd year of remission on ATN decreased from 2.7 to 2.0 in parallel with the reduction of positive signs by P + G; on TN there was an increase in MS indices of subscale N from 2.3 to 2.7 scores. The assessment of negative disorders is discussed as “secondary” negative due to the phenomenologically is assumed with the symptoms of the positive syndrome and the effects of neurolepsy. Conclusion: TN and ATN exhibit a similar “antipsychotic” effect in the treatment of acute paranoid psychoses in shift-like schizophrenia patients with the formation of long-term high quality remissions, stabilization of degrees of reducted productive psychopathological symptoms and with the absence of the progredience disease. To optimize the therapeutic effect of both types of antipsychotics, it is recommended correction of the regime and the term in transition from active to maintenance therapy and prescription of neurolepsy correctors to reduce severity in the picture of “secondary” negative symptoms.

The atypical neuroleptics iloperidone and lurasidone inhibit human cytochrome P450 enzymes in vitro. Evaluation of potential metabolic interactions

Background The present study aimed at examining the inhibitory effect of two atypical neuroleptics iloperidone and lurasidone on the main human cytochrome P450 (CYP) enzymes in pooled human liver microsomes and cDNA-expressed CYP enzymes (supersomes). Methods The activity of these enzymes was determined by the following CYP-specific reactions: caffeine 3-N-demethylation/CYP1A2, diclofenac 4′-hydroxylation/CYP2C9, perazine N-demethylation/CYP2C19, bufuralol 1′-hydroxylation/CYP2D6 and testosterone 6β-hydroxylation/CYP3A4, respectively, using HPLC. Results Iloperidone inhibited the activity of CYP3A4 via a noncompetitive mechanism (Ki = 0.38 and 0.3 µM in liver microsomes and supersomes, respectively) and CYP2D6 via a competitive mechanism (Ki = 2.9 and 10 µM in microsomes and supersomes). Moreover, iloperidone attenuated the activity of CYP1A2 (Ki = 45 and 31 µM in microsomes and supersomes) and CYP2C19 via a mixed mechanism (Ki = 6.5 and 32 µM in microsomes and supersomes) but did not affect CYP2C9. Lurasidone moderately inhibited CYP1A2 (Ki = 12.6 and 15.5 µM in microsomes and supersomes), CYP2C9 (Ki = 18 and 3.5 µM in microsomes and supersomes) and CYP2C19 via a mixed mechanism (Ki = 18 and 18.4 µM in microsomes and supersomes), and CYP3A4 via a competitive mechanism (Ki = 29.4 and 9.1 µM in microsomes and supersomes). Moreover, lurasidone competitively, though weakly diminished the CYP2D6 activity (Ki = 37.5 and 85 µM in microsomes and supersomes). Conclusion The examined neuroleptics showed inhibitory effects on different CYP enzymes. The obtained results indicate that metabolic/pharmacokinetic interactions with iloperidone (involving mainly CYP3A4 and CYP2D6) and possibly with lurasidone (involving CYP1A2, CYP2C9 or CYP2C19) may occur during combined therapy.

Paranoid Schizophrenia - Clinical and Therapeutic Correlations

Schizophrenia is a serious psychosis that appears in young adult, usually chronic, characterised by signs of mental dissociation and incoherent delirious activity that determines the breaking of the contact with the exterior world. The primary objective of this study is to compare the efficiency of Haloperidol and Risperidone. The study consisted in enrolling, evaluating and the clinical and therapeutic following of 125 patients hospitalised at the Clinic Hospital of Psychiatry..., in Galai, between 2000 and 2015. They were divided into 4 equal sub-lots according to the medication received. The modern treatment consists in the administration of atypical neuroleptics, such as: Risperidone, Olanzapine, Clozapine, etc. These substances proved their efficiency in the negative and affective symptoms together with the increase of therapeutic compliance due to the absent secondary effects. The precocious diagnostic, the modern anti-psychotic treatment from its first manifestations and maintained in order to avoid relapse, improve greatly the prognostic in the long run.

Eating Disorders in Schizophrenia

BackgroundDue to their frequency and negative impact on quality of life, eating disorders in schizophrenia need to be considered and highlighting.ObjectiveTo identify the risk of eating disorders (ED) and its correlates among mental patients.MethodsIt was a descriptive and analytic study. It included 53 inpatients with DSM-5 diagnoses of schizophrenia or schizoaffective disorder, followed in the department of Psychiatry at the Hedi Chaker University Hospital of Sfax in Tunisia, during the three months of August, September and October 2016. Data collections were conducted using questionnaire exploring sociodemographic and medical data. The SCOFF (sick, control, one, fat, food) Questionnaire was used to screen ED. A total score of ≥ 2 was used as a cutoff point to select persons at risk of ED.ResultsThe average age of our patients was 30.47 ± 9.5 years old. The majority of our patients was male (71.7%) and single (71%). The mean of extra Body mass was 27.9. The mean duration of disease was 9.9 ± 8.1 years and patients were mostly (54%) in atypical neuroleptics. According to the SCOFF Questionnaire, 35.8% had a risk of ED. Female gender and treatment with atypical neuroleptics were significantly associated to ED risk with respectively P = 0.02 and P = 0.038.ConclusionEating disorders remain underestimated among patients suffering from schizophrenia. Yet, its screening prevention and management are crucial and must be multidisciplinary for optimal care.Disclosure of interestThe authors have not supplied their declaration of competing interest.